The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).
R. Kurzrock
Research Funding - GlaxoSmithKline
A. Patnaik
Research Funding - GlaxoSmithKline
L. Rosenstein
Employment or Leadership Position - GlaxoSmithKline
S. Fu
No relevant relationships to disclose
K. P. Papadopoulos
Research Funding - GlaxoSmithKline
D. A. Smith
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. S. Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
G. Chambers
No relevant relationships to disclose
J. L. Gauvin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. Naing
No relevant relationships to disclose
L. S. Smith
No relevant relationships to disclose
T. Gonzalez
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. M. Tsimberidou
No relevant relationships to disclose
T. A. Mays
Research Funding - Merck
D. S. Cox
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
D. S. Hong
No relevant relationships to disclose
D. J. DeMarini
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
N. T. Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
S. R. Morris
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International; Abraxis BioScience; Actavis; Adnexus; Ambit BioSciences; Amgen; ARIAD; Arresto; Astellas Pharma; Bayer; BIND Biosciences; Biogen Idec; Chemokine; Curis; Dendreon; Dicerna; Endo Pharmaceuticals; Enzon; Exelixis; FivePrime; Genentech; Geron; GlaxoSmithKline; HUYA Bioscience International; Insert Therapeutics; Intellikine; Johnson & Johnson; Merck; Micromet; Nektar (U); Novartis; Ortho Biotech; Otsuka; Pfizer; PPD Development; ProNAi; Regeneron; Sanofi ; Santaris; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex; Veeda Oncology
Research Funding - Abbott Laboratories; Adnexus; Ambit BioSciences; Amgen; ArQule; Array BioPharma; Arresto; Astellas Pharma; AVEO; Azaya Therapeutics; Bayer; Biogen Idec; BiPar Sciences; Bristol-Myers Squibb; Calando; Centocor Ortho Biotech; Coronado Biosciences; Cougar Biotechnology; Curis; Cyclacel; Cylene; Daiichi Sankyo; Dendreon; Enzon; Exelixis; FivePrime; Genentech; Genta; GlaxoSmithKline; Hana BioSciences; Immunogen; Lilly; Merck; Merrimack; MethylGene; Millennium; Myrexis; Nektar; Nerviano; Novartis; OncoMed; Onyx; Ortho Biotech; Pfizer; Pfizer; PharmaMar; Proacta; ProNAi; Provia Biologics; Roche; Sanofi ; Schering-Plough; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex